Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D02AIC
|
||||
Former ID |
DIB004413
|
||||
Drug Name |
CP-870893
|
||||
Synonyms |
Fully human CD40 agonist antibody, Pfizer; CD40 ligand (cancer), Pfizer
|
||||
Drug Type |
Antibody
|
||||
Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Phase 1 | [523006] | ||
Company |
Pfizer Inc
|
||||
Target and Pathway | |||||
Target(s) | Tumor necrosis factor ligand superfamily member 5 | Target Info | [532263], [532466] | ||
KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
NF-kappa B signaling pathway | |||||
Cell adhesion molecules (CAMs) | |||||
T cell receptor signaling pathway | |||||
Intestinal immune network for IgA production | |||||
Malaria | |||||
Toxoplasmosis | |||||
Asthma | |||||
Autoimmune thyroid disease | |||||
Systemic lupus erythematosus | |||||
Allograft rejection | |||||
Primary immunodeficiency | |||||
Viral myocarditis | |||||
References | |||||
Ref 532263 | Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology. 2013 Jan 1;2(1):e23033. | ||||
Ref 532466 | A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res. 2013 Nov 15;19(22):6286-95. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.